Search results for "Coagulant"

showing 10 items of 342 documents

Use of oral anticoagulant drugs in older patients with atrial fibrillation in internal medicine wards

2018

no abstract available

MaleAdministration Oral030204 cardiovascular system & hematologyBody Mass IndexOral anticoagulant drug0302 clinical medicineElderlyDrug PrescriptionOlder patientsRetrospective Studie80 and overMedicine030212 general & internal medicineStrokeRandomized Controlled Trials as TopicAged 80 and overAtrial fibrillation; Elderly; Oral anticoagulant drugs; Prescription rate; Internal MedicineAtrial fibrillationStrokeObservational Studies as TopicAtrial fibrillation Elderly Oral anticoagulant drugs Prescription rate Internal MedicineAdministrationOral anticoagulantFemaleHumanOralmedicine.medical_specialtyOral anticoagulant drugsSocio-culturaleDrug Prescriptions03 medical and health sciencesInternal medicineInternal MedicineHumansPrescription rateAgedRetrospective Studiesbusiness.industrySettore MED/09 - MEDICINA INTERNAAnticoagulantAnticoagulantsRetrospective cohort studymedicine.diseaseAtrial fibrillationAtrial fibrillation; Elderly; Oral anticoagulant drugs; Prescription rate; Administration Oral; Aged; Aged 80 and over; Anticoagulants; Atrial Fibrillation; Body Mass Index; Drug Prescriptions; Female; Humans; Internal Medicine; Male; Observational Studies as Topic; Randomized Controlled Trials as Topic; Retrospective Studies; Stroke; Internal MedicineObservational Studies as TopicbusinessBody mass indexAtrial fibrillation Elderly Oral anticoagulant drugs Prescription rate
researchProduct

The prescription of direct oral anticoagulants in the elderly: An observational study of 19 798 Ambulatory subjects.

2020

International audience; Objective Direct oral anticoagulants (DOACs) are increasingly prescribed to elderly people, but the epidemiologic data for this population remains scarce. We compared the elderly population taking DOACs and those not taking DOACs (noDOAC). Method We included individuals over 75 years old, affiliated to Mutualite Sociale Agricole of Burgundy (a French regional health insurance agency), who had been refunded for a prescribed DOAC between 1st and 30th September 2017. The DAOC group (DAOCG) and noDOAC group (noDOACG) were compared in terms of demographic conditions, registered chronic diseases (RCD), and number and types of prescribed drugs. In the DOACG, we compared the…

MaleAdministration Oral030204 cardiovascular system & hematologyKidney Function Tests0302 clinical medicineRivaroxabanMedicineDisease030212 general & internal medicineProspective StudiesPractice Patterns Physicians'Aged 80 and overeducation.field_of_studyFrailtyVenous ThromboembolismGeneral MedicineMetaanalysisManagement3. Good healthDabigatranHealthCreatinineAmbulatoryPlatelet aggregation inhibitorApixabanFemaleBlood Coagulation TestsFranceSafetymedicine.drugmedicine.medical_specialtyPyridonesPopulationDrug PrescriptionsDabigatran03 medical and health sciencesInternal medicineHumansMedical prescriptioneducationAntihypertensive AgentsAgedRivaroxabanbusiness.industryWarfarinAnticoagulantsBlood Cell CountAtrial-FibrillationChronic DiseasePyrazolesWarfarinbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyPlatelet Aggregation InhibitorsInternational journal of clinical practiceREFERENCES
researchProduct

Management of Oral Anti-Coagulation in Patients with Heart Failure-Insights from the ThrombEVAL Study

2018

AbstractPatients with heart failure (HF) are frequently anti-coagulated with vitamin K-antagonists (VKAs). The use of long-acting VKA may be preferable for HF patients due to higher stability of plasma concentrations. However, evidence on phenprocoumon-based oral anti-coagulation (OAC) therapy in HF is scarce. The aim of this study was to assess the impact of the presence of HF on quality of phenprocoumon-based OAC and the subsequent clinical outcome. Quality of OAC therapy and the incidence of adverse events were analysed in a cohort of regular care (n = 2,011) from the multi-centre thrombEVAL study program (NCT01809015) stratified by the presence of HF. To assess the modifiability of outc…

MaleAdministration Oralheart failureclinical outcomeED AMERICAN-COLLEGE030204 cardiovascular system & hematologyTHERAPY ANTITHROMBOTIC THERAPYCohort StudiesPhenprocoumon0302 clinical medicinequality of careGermanyProspective Studies030212 general & internal medicineProspective cohort studyAged 80 and overOUTCOMESIncidenceHazard ratioHematologyTreatment OutcomeCohortFemaleCLINICAL-PRACTICE GUIDELINESSINUS RHYTHMmedicine.drugCohort studyRiskmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsHemorrhageWARFARINEJECTION FRACTION03 medical and health sciencesInternal medicinemedicineHumansAdverse effectAgedbusiness.industryWarfarinhealth care modelAnticoagulantsmedicine.diseaseoral anti-coagulationHeart failureATRIAL-FIBRILLATIONPhenprocoumonADVERSE EVENTSbusinessANTICOAGULANT-THERAPY
researchProduct

Antiphospholipid antibodies in pediatric patients with prolonged activated partial thromboplastin time during infection.

2005

Abstract Objective To investigate the close association between different antiphospholipid antibodies (aPL) caused by infection and their appearance together with a prolonged activated partial thromboplastin time (aPTT). Methods Sera from 122 children were evaluated in this study. Thirty-seven children with mild to medium prolonged aPTT (>37.2 s) and elevated C-reactive protein (CRP) levels during various forms of infections (group 2), 18 children without infections (group 3) but with mild to medium prolonged aPTT and 13 children with infections (group 4) and with elevated CRP-level as well as a control group (group 1) of 54 patients without any infection and normal aPTT and negative CRP le…

MaleAdolescentFeverImmunologyInfectionsImmunoglobulin Gchemistry.chemical_compoundCardiolipinmedicineImmunology and AllergyHumansChildLupus anticoagulantbiologymedicine.diagnostic_testbusiness.industryC-reactive proteinInfantHematologyPhosphatidylserinemedicine.diseaseC-Reactive ProteinchemistryImmunoglobulin MImmunoglobulin MChild PreschoolImmunoglobulin GImmunologybiology.proteinAntibodies AntiphospholipidFemalePartial Thromboplastin TimeAntibodybusinessPartial thromboplastin timeImmunobiology
researchProduct

Prescription of Antithrombotic Therapy in Older Patients Hospitalized for Transient Ischemic Attack and Ischemic Stroke: The GIFA Study

2004

Background and Purpose— Antithrombotic therapy has been demonstrated as an effective tool for secondary ischemic stroke prevention. Nevertheless, scant data are available on actual prescription of this therapy in clinical practice. Methods— A total of 17 337 patients admitted to geriatric and internal medicine wards participating in the study in the 1993 to 1998 survey period were analyzed. Patients with coded diagnoses of ischemic stroke and transient ischemic attack (TIA) were selected. Data recorded included demographic and clinical characteristics and medication prescription during hospital stay and at discharge. Logistic regression analyses were used to identify conditions associated …

MaleAgingmedicine.medical_specialtypharmacoepidemiologyEpidemiologymedicine.drug_classIschemiaMedication prescriptionNOBrain Ischemiastroke; prevention; aging; antithrombotic therapy; pharmacoepidemiologypreventionFibrinolytic AgentsEpidemiologyAntithromboticmedicineHumansMedical prescriptionStrokeAgedDemographyAntithrombotic therapyAdvanced and Specialized Nursingbusiness.industryAnticoagulantAnticoagulantsOdds ratiomedicine.diseaseHospitalizationStrokeIschemic Attack TransientAcute DiseaseEmergency medicinePhysical therapyFemaleNeurology (clinical)Cardiology and Cardiovascular MedicinebusinessPlatelet Aggregation InhibitorsStroke
researchProduct

Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study

2018

Background: Among rate-control or rhythm-control strategies, there is conflicting evidence as to which is the best management approach for non-valvular atrial fibrillation (AF) in elderly patients. Design: We performed an ancillary analysis from the ‘Registro Politerapie SIMI’ study, enrolling elderly inpatients from internal medicine and geriatric wards. Methods: We considered patients enrolled from 2008 to 2014 with an AF diagnosis at admission, treated with a rate-control-only or rhythm-control-only strategy. Results: Among 1114 patients, 241 (21.6%) were managed with observation only and 122 (11%) were managed with both the rate- and rhythm-control approaches. Of the remaining 751 patie…

MaleAnti-Arrhythmia Agents/therapeutic useantiarrhythmic agentComorbidityAged; Aged 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Diabetes Mellitus; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Male; Odds Ratio; Polypharmacy; Prevalence; Geriatrics and Gerontology; Pharmacology (medical)030204 cardiovascular system & hematologyanticoagulant agentDiabetes Mellitus/drug therapy0302 clinical medicineHeart RateAtrial Fibrillation80 and overOdds RatioPrevalencePharmacology (medical)030212 general & internal medicineLS4_4Aged 80 and overantiarrhythmic agent anticoagulant agent antithrombocytic agent calcium channel blocking agent digoxinHeart Rate/drug effectsDiabetes MellituAtrial fibrillationantithrombocytic agentdigoxinHospitalizationAnti-Arrhythmia AgentFemaleAnti-Arrhythmia AgentsHumanmedicine.medical_specialtySocio-culturale-Geriatrics and Gerontology; Pharmacology (medical)03 medical and health sciencesInternal medicineDiabetes mellitusHeart rateantiarrhythmic agent; anticoagulant agent; antithrombocytic agent; calcium channel blocking agent; digoxinmedicineDiabetes MellitusHumansAgedPolypharmacyHeart Failurebusiness.industryAtrial Fibrillation/drug therapyOdds ratiomedicine.diseaseHeart Failure/drug therapyComorbidityConfidence intervalcalcium channel blocking agentHeart failurePolypharmacyAged; Aged 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Diabetes Mellitus; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Male; Odds Ratio; Polypharmacy; PrevalenceGeriatrics and Gerontologybusiness
researchProduct

Fondaparinux and enoxaparin in comparison to unfractionated heparin in preventing thrombus formation on mechanical heart valves in an ex vivo rabbit …

2003

SummaryThe aim of the present study was to investigate the efficacy of three different parenterally administered anticoagulants for the prevention of thrombus formation on artificial heart valves in an experimental rabbit model.Unfractionated heparin was administered intravenously in group I (n = 10), Enoxaparin subcutaneously in group II (n = 10), fondaparinux intravenously in group III (n = 10), and no medication was administered to group IV (n = 9). Leaflets from Sulzer Carbomedics bileaflet mechanical heart valves were placed in a flow chamber. The flow chamber was filled with blood in a continuous circulation between the carotid artery and the jugular vein.In group IV the flow chamber …

MaleArtificial heart valvemedicine.drug_classmedicine.disease_causeFondaparinuxPolysaccharidesmedicineAnimalsHeart valveEnoxaparinThrombusHeparinbusiness.industryAnticoagulantAnticoagulantsThrombosisHematologyHeparinmedicine.diseaseFondaparinux SodiumMicroscopy Electronmedicine.anatomical_structureFondaparinuxHeart Valve ProsthesisAnesthesiaBlood Coagulation TestsRabbitsbusinessEnoxaparin sodiummedicine.drugThrombosis and Haemostasis
researchProduct

Recanalization Therapies in Acute Ischemic Stroke Patients Impact of Prior Treatment With Novel Oral Anticoagulants on Bleeding Complications and Out…

2015

Background— We explored the safety of intravenous thrombolysis (IVT) or intra-arterial treatment (IAT) in patients with ischemic stroke on non-vitamin K antagonist oral anticoagulants (NOACs, last intake <48 hours) in comparison with patients (1) taking vitamin K antagonists (VKAs) or (2) without previous anticoagulation (no-OAC). Methods and Results— This is a multicenter cohort pilot study. Primary outcome measures were (1) occurrence of intracranial hemorrhage (ICH) in 3 categories: any ICH (ICH any ), symptomatic ICH according to the criteria of the European Cooperative Acute Stroke Study II (ECASS-II) (sICH ECASS-II ) and the National Institute of Neurological Disorders and Stroke …

MaleBrain Ischemia/blood/drug therapyVitamin Kmedicine.medical_treatmentendovascular proceduresAnticoagulants/administration & dosage/adverse effects/classification/therapeutic useAdministration OralPilot ProjectsTissue plasminogen activatorBrain IschemiaCohort Studies2737 Physiology (medical)Atrial Fibrillation80 and overThrombolytic TherapyVitamin K/antagonists & inhibitorsStrokethrombolytic therapyAged 80 and overIncidenceAtrial fibrillationThrombolysisMiddle Aged3. Good healthvitamin K antagonistsTreatment OutcomeAdministrationAcute DiseaseCohortCerebral Hemorrhage/chemically induced/epidemiologyFemaleCardiology and Cardiovascular MedicineAtrial Fibrillation/complicationsmedicine.drugOralmedicine.medical_specialtyanticoagulantsnon-vitamin K antagonist oral anticoagulantsFactor Xa Inhibitors/administration & dosage/adverse effects/therapeutic useintracranial hemorrhagesintra-arterial treatment610 Medicine & healthAntithrombins2705 Cardiology and Cardiovascular MedicineDabigatranFibrinolytic AgentsPhysiology (medical)Internal medicinemedicineischemic strokeHumansAgedCerebral HemorrhageIntracerebral hemorrhageFibrinolytic Agents/therapeutic usebusiness.industryAntithrombins/administration & dosage/adverse effects/therapeutic usemedicine.diseaseddc:616.810040 Clinic for Neurologyanticoagulants; endovascular procedures; intra-arterial treatment; intracranial hemorrhages; ischemic stroke; non-vitamin K antagonist oral anticoagulants; thrombolytic therapy; vitamin K antagonistsPropensity score matchingbusinessFactor Xa InhibitorsCirculation
researchProduct

Gene therapy with iNOS enhances regional contractility and reduces delayed contrast enhancement in a model of postischemic congestive heart failure

2012

Aims: The purpose of this study was to evaluate the effect of transient local myocardial gene transfer of iNOS on cardiac function in a large mammal animal model of heart failure induced by chronic ischemia. Methods: Chronic myocardial ischemia was induced using a minimally invasive model in 16 landrace pigs. Upon demonstration of heart failure, eight animals were treated with liposome-mediated iNOS-gene-transfer by local intramyocardial injection; eight animals received a sham procedure to serve as control. Results: The transmurality of late enhancement (control: 46.4%, iNOS: 35.9%; p < 0.05) was significantly decreased in the ischemic area in the iNOS-treated group. Wall thickness at end-…

MaleCardiac function curvemedicine.medical_specialtyTiclopidineSwinePhysiologySus scrofaMyocardial IschemiaIschemiaContrast MediaNitric Oxide Synthase Type IIGadoliniumCoronary AngiographyContractilityRandom AllocationVentricular Dysfunction LeftGenes ReporterFibrosisPhysiology (medical)Internal medicineGenes SyntheticmedicineAnimalsTiclopidineHeart FailureDrug CarriersAspirinAspirinmedicine.diagnostic_testbusiness.industryCoronary StenosisAnticoagulantsMagnetic resonance imagingGenetic TherapyHematologymedicine.diseaseFibrosisMagnetic Resonance ImagingMyocardial ContractionClopidogrelDisease Models AnimalHeart failureLiposomesCardiologyFemaleStentsCardiology and Cardiovascular Medicinebusinessmedicine.drugClinical Hemorheology and Microcirculation
researchProduct

Effect of serum protein binding on pharmacokinetics and anticoagulant activity of phenprocoumon in rats.

1980

The relationship among serum protein binding, kinetics of elimination, distribution, and anticoagulant activity of phenprocoumon was investigated in 25 selected outbred Sprague-Dawley rats which differed in the extent of serum protein binding of this drug. In addition, the serum protein binding of phenprocoumon was altered in inbred Lewis rats by continuous treatment with tolbutamide. This drug was found to displace phenprocoumon from serum proteins without affecting its intrinsic clearance. The serum free fraction values (fs)of the selected Sprague-Dawley rats ranged from 0.0053 to 0.0145. There were positive and linear correlations between fsand the first-order elimination rate constant (…

MaleChemistryTolbutamideAnticoagulantsPlasma protein binding4-HydroxycoumarinsBlood ProteinsPharmacologyBlood proteinsRatsPhenprocoumonKineticsTolbutamideElimination rate constantPharmacokineticsFree fractionmedicinePhenprocoumonDistribution (pharmacology)AnimalsPharmacology (medical)General Pharmacology Toxicology and Pharmaceuticsmedicine.drugProtein BindingJournal of pharmacokinetics and biopharmaceutics
researchProduct